Drug Trial Radar · NCT07856511
A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
590
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Apr 1, 2027
Study completion Sep 30, 2028
Sponsor
- Lead sponsor
- Jiankuan (Suzhou) Biotechnology Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy and safety of different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs
Conditions
- Rheumatoid Arthrits
Interventions
PlaceboDrug
The placebo group will take drugs orally for 16 weeks, and then were randomly assigned to proximod dose 1 and proximod dose 2 for 36 weeks, in the meanwhile, proximod dose 1 group and proximod dose 2 group will continue taking drugs for the whole 52 weeks.
ProximodDrug
The placebo group will take drugs orally for 16 weeks, and then were randomly assigned to proximod dose 1 and proximod dose 2 for 36 weeks, in the meanwhile, proximod dose 1 group and proximod dose 2 group will continue taking drugs for the whole 52 weeks.
ProximodDrug
The placebo group will take drugs orally for 16 weeks, and then were randomly assigned to proximod dose 1 and proximod dose 2 for 36 weeks, in the meanwhile, proximod dose 1 group and proximod dose 2 group will continue taking drugs for the whole 52 weeks.
PlaceboDrug
The placebo group will take drugs orally for 16 weeks, and then switch to proximod for 36 weeks, in the meanwhile, proximod group will continue taking drugs for the whole 52 weeks.
ProximodDrug
The placebo group will take drugs orally for 16 weeks, and then switch to proximod for 36 weeks, in the meanwhile, proximod group will continue taking drugs for the whole 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACR20 response rate at week 16(Phase I and Phase II)Time frame: Week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.